Senlang Bio Launches Commercial Cell Therapy Production Base with $17 Million Investment

SenlangbioIt is a high-tech enterprise specializing in the research, production, and commercialization of cell therapy products. The company is committed to promoting the clinical application of cell therapy through leading technology and innovative solutions, benefiting a wide range of patients.

Since its establishment in 2016, the company has grown continuously and now possesses a 14,000㎡ R&D and production base built according to international standards. It has established a one-stop cell therapy drug R&D and industrialization platform, as well as a nanobody development and screening platform. The company has mastered core technologies such as large-scale plasmid preparation, lentiviral vector preparation, and primary immune cell preparation, successfully establishing a full-process CAR-T industrial chain in China. The company has six cell therapy pipelines under development, three of which are in the registration phase of clinical research. The company’s CD7-targeted CAR-T product, aimed at relapsed or refractory T lymphoblastic lymphoma/leukemia, utilizes a unique "natural selection" technology platform that does not require gene editing for CD7. It has demonstrated good safety and efficacy in IIT (investigator-initiated trials), with related data published in the internationally authoritative journals Blood and American Journal of Hematology. This product is currently in Phase I registered clinical trials in China and was granted Orphan Drug Designation (ODD) by the U.S. FDA in August 2023. Globally, there are currently no approved CD7-targeted CAR-T products on the market. The company's CD19-targeted CAR-T product for B-cell acute lymphoblastic leukemia is also currently in Phase I registered clinical trials in China.

Source: Official senlangbio